Beta-1,4-galactosyltransferase 1

B4GALT1 human recombinant, expressed in HEK 293 cells, 2000 units/mg protein

UDP-galactose:beta-N-acetylglucosamine beta-1,4-galactosyltransferase 1, b4Gal-T1, Beta4Gal-T1, Beta-1,4-GalTase 1, UDP-Gal:beta-GlcNAc beta-1,4-galactosyltransferase 1
En este momento no podemos mostrarle ni los precios ni la disponibilidad


expressed in HEK 293 cells


95% (SDS-PAGE)


lyophilized powder

specific activity

2000 units/mg protein

shipped in


storage temp.


General description

Recombinant human Beta-1,4-galactosyltransferase 1 (B4GALT1) is expressed in human HEK 293 cells as a glycoprotein with a calculated molecular mass of 40 kDa. The DTT-reduced protein migrates as a ~55 kDa polypeptide on SDS-PAGE due to glycosylation. This protein is manufactured in human cells, with no serum. The human cells expression system allows human-like glycosylation and folding, and often supports higher specific activity of the protein.


This recombinant B4GALT1 product can be used to study the mode of action of the enzyme, as well as its potential inhibitors. It can also be used as a glycoengineering tool to modify glycoproteins in vitro.

Biochem/physiol Actions

β(1→4) galactosyltransferase 1 (B4GALT1) is a type II membrane-bound glycoprotein that transfers galactose from uridine diphosphate-α-D-galactose (UDP-galactose) to acceptor sugars, such as N-Acetylglucosamine (GlcNAc), in a β(1→4) linkage. B4GALT1 resides in the Golgi apparatus of higher eukaryotic cells.
A major function of B4GALT1 is the addition of β(1→4) linked galactose residues to oligosaccharide acceptors with terminal N-acetylglucosamine residues. This is a late elongation step in the N-glycan processing pathway.B4GALT1 enzymatic activity is widely distributed in the vertebrate kingdom, in both mammals and non-mammals, including avians and amphibians.B4GALT1 enzymatic activity has also been demonstrated in a subset of plants which diverged from animals an estimated 1 billion years ago.B4GALT1 interacts with α-lactalbumin (LA), a protein expressed in the mammary gland during lactation, to form the lactose synthase (LS) complex that transfers galactose from UDP-α-D-Gal to glucose, producing the lactose secreted in milk.Defects in B4GALT1 are the cause of congenital disorder of glycosylation type 2D (CDG2D).Glomerular B4GALT1 expression has been found to be increased in IgA nephropathy. IgA binding and IgA-induced mesangial cell phosphorylation of spleen tyrosine kinase and IL-6 synthesis were inhibited by a panel of β(1→4) galactosyltransferase-specific antibodies, which suggests that IgA binds to the catalytic domain of β(1→4) galactosyltransferase.

Unit Definition

One unit is defined as the amount of enzyme required to transfer 1.0 nanomole of galactose from UDP-Gal to glucosamine per minute at pH 7.9, 37 oC.


NONH for all modes of transport

WGK Germany


Flash Point F

Not applicable

Flash Point C

Not applicable

Verena Janes et al.
Cells, 9(3) (2020-03-07)
Genetic defects of human galactose-1-phosphate uridyltransferase (hGALT) and the partial loss of enzyme function result in an altered galactose metabolism with serious long-term developmental impairment of organs in classic galactosemia patients. In search for cellular pathomechanisms induced by the stressor...
Glycosyltransferases were initially considered to be specific for a single glycosyl donor and acceptor, which led to the one enzyme-one linkage concept. Subsequent observations have refuted the theory of absolute enzymatic specificity by describing the transfer of analogs of some nucleoside mono- or diphosphate sugar donors.
Más información

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.